33 "Melanoma" clinical trials found.
-
A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
This study wants to find out if a new treatment called V940, when used with pembrolizumab, has fewer side effects and is more effective than ...
-
A Phase 2 Open-label Multicenter Cohort Study of ALKS 4230 Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6
The purpose of the study is to evaluate the antitumor activity, safety and tolerability of ALKS 4230 given as monotherapy in patients with unresectable and ... -
An open-label multi-center phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors
This is a medical study for adults with advanced solid tumors. The study has two parts: the first part tests different doses of a drug ...
-
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
You can participate in this study if you are diagnosed with skin melanoma stage 2. This study will determine whether there is a difference in ... -
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage IV Melanoma
This study is looking at a treatment for advanced melanoma, a type of skin cancer. The study has two parts. First, patients will get a ...
-
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) [EA6192]
The purpose of the study is to evaluate and determine how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients ... -
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors
You may qualify for this study if you have metastatic or unresectable melanoma or other advanced solid tumors. This study will include three phases: a ...
-
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
This is a phase 3 clinical trial that compares the effectiveness of two different treatment options in patients who have undergone surgery to remove high-risk ...
-
Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
The purpose of the study is to determine and to evaluate the safety as well as efficacy of investigational treatment arms with or without pembrolizumab ... -
A Phase 3 Randomized Double-blind Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This research study is for people who are 12 years of age or older and weigh at least 40 kg, and who have had surgery ...